0001209191-24-004438.txt : 20240305
0001209191-24-004438.hdr.sgml : 20240305
20240305181005
ACCESSION NUMBER: 0001209191-24-004438
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240229
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RENSCHLER MARKUS MD
CENTRAL INDEX KEY: 0001217598
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40499
FILM NUMBER: 24723006
MAIL ADDRESS:
STREET 1: C/O PHARMACYCLICS INC
STREET 2: 995 E ARQUES AVE
CITY: SUNNYVALE
STATE: CA
ZIP: 94085-4521
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662244
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 455429901
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE
STREET 2: BUILDING B, SUITE 450
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 857-285-4140
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE
STREET 2: BUILDING B, SUITE 450
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-02-29
0
0001662244
Cyteir Therapeutics, Inc.
CYT
0001217598
RENSCHLER MARKUS MD
C/O CYTEIR THERAPEUTICS, INC.
99 HAYDEN AVE, BUILDING B, SUITE 450
LEXINGTON
MA
02421
1
1
0
0
President and CEO
0
Common Stock
2024-02-29
4
M
0
12607
1.69
A
1094820
D
Common Stock
2024-02-29
4
M
0
2537
1.20
A
1097357
D
Common Stock
2024-03-04
4
M
0
6304
1.69
A
1103661
D
Stock Option (Right to Buy)
1.69
2024-02-29
4
M
0
12607
0.00
D
2033-02-03
Common Stock
12607
226952
D
Stock Option (Right to Buy)
1.20
2024-02-29
4
M
0
2537
0.00
D
2024-02-01
2030-02-24
Common Stock
2537
0
D
Stock Option (Right to Buy)
1.69
2024-03-04
4
M
0
6304
0.00
D
2033-02-03
Common Stock
6304
220648
D
The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
/s/ David Gaiero, as attorney-in-fact for Markus Renschler, M.D.
2024-03-05